User login
Key clinical point: A dose of 60 mg atogepant once daily was safe and well tolerated and demonstrated early efficacy sustained over 1 year in patients with episodic migraine.
Major finding: Treatment-emergent adverse events (TEAE), mostly mild or moderate, occurred in 67.0% vs 78.6% of patients receiving atogepant vs oral standard care, respectively. Serious TEAE occurred in 4.4% of atogepant-treated patients; however, treatment discontinuation due to adverse events (<6%) and lack of efficacy (<1%) was rare. Overall, 60.4% and 84.2% of patients reported ≥50% reduction in monthly migraine days during weeks 1-4 and 49-52 of atogepant treatment, respectively.
Study details: This open-label phase 3 trial included 744 patients with migraine with or without aura who were randomly assigned to receive 60 mg atogepant or oral standard care migraine preventive medication.
Disclosures: This study was sponsored by Allergan/AbbVie. Five authors declared being current or former employees of or holding stocks in AbbVie. Several authors declared serving as a consultants, speakers, scientific advisors, or primary investigators for AbbVie and other sources.
Source: Ashina M et al. Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial. Headache. 2023;63:79-88 (Jan 18). Doi: 10.1111/head.14439
Key clinical point: A dose of 60 mg atogepant once daily was safe and well tolerated and demonstrated early efficacy sustained over 1 year in patients with episodic migraine.
Major finding: Treatment-emergent adverse events (TEAE), mostly mild or moderate, occurred in 67.0% vs 78.6% of patients receiving atogepant vs oral standard care, respectively. Serious TEAE occurred in 4.4% of atogepant-treated patients; however, treatment discontinuation due to adverse events (<6%) and lack of efficacy (<1%) was rare. Overall, 60.4% and 84.2% of patients reported ≥50% reduction in monthly migraine days during weeks 1-4 and 49-52 of atogepant treatment, respectively.
Study details: This open-label phase 3 trial included 744 patients with migraine with or without aura who were randomly assigned to receive 60 mg atogepant or oral standard care migraine preventive medication.
Disclosures: This study was sponsored by Allergan/AbbVie. Five authors declared being current or former employees of or holding stocks in AbbVie. Several authors declared serving as a consultants, speakers, scientific advisors, or primary investigators for AbbVie and other sources.
Source: Ashina M et al. Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial. Headache. 2023;63:79-88 (Jan 18). Doi: 10.1111/head.14439
Key clinical point: A dose of 60 mg atogepant once daily was safe and well tolerated and demonstrated early efficacy sustained over 1 year in patients with episodic migraine.
Major finding: Treatment-emergent adverse events (TEAE), mostly mild or moderate, occurred in 67.0% vs 78.6% of patients receiving atogepant vs oral standard care, respectively. Serious TEAE occurred in 4.4% of atogepant-treated patients; however, treatment discontinuation due to adverse events (<6%) and lack of efficacy (<1%) was rare. Overall, 60.4% and 84.2% of patients reported ≥50% reduction in monthly migraine days during weeks 1-4 and 49-52 of atogepant treatment, respectively.
Study details: This open-label phase 3 trial included 744 patients with migraine with or without aura who were randomly assigned to receive 60 mg atogepant or oral standard care migraine preventive medication.
Disclosures: This study was sponsored by Allergan/AbbVie. Five authors declared being current or former employees of or holding stocks in AbbVie. Several authors declared serving as a consultants, speakers, scientific advisors, or primary investigators for AbbVie and other sources.
Source: Ashina M et al. Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial. Headache. 2023;63:79-88 (Jan 18). Doi: 10.1111/head.14439